Celldex Therapeutics, Inc. $CLDX Shares Sold by UBS Group AG

UBS Group AG reduced its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 21.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 326,462 shares of the biopharmaceutical company’s stock after selling 89,985 shares during the period. UBS Group AG’s holdings in Celldex Therapeutics were worth $8,867,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Celldex Therapeutics by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 4,027,407 shares of the biopharmaceutical company’s stock worth $109,384,000 after purchasing an additional 72,817 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in shares of Celldex Therapeutics by 67.2% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 32,263 shares of the biopharmaceutical company’s stock worth $876,000 after purchasing an additional 12,966 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Celldex Therapeutics by 11.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 25,317 shares of the biopharmaceutical company’s stock worth $688,000 after purchasing an additional 2,517 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Celldex Therapeutics by 31.2% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 46,965 shares of the biopharmaceutical company’s stock worth $1,276,000 after purchasing an additional 11,182 shares during the last quarter. Finally, Mirador Capital Partners LP boosted its holdings in shares of Celldex Therapeutics by 2.9% during the 4th quarter. Mirador Capital Partners LP now owns 170,659 shares of the biopharmaceutical company’s stock worth $4,635,000 after purchasing an additional 4,738 shares during the last quarter.

Wall Street Analysts Forecast Growth

CLDX has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Monday, April 20th. The Goldman Sachs Group boosted their target price on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a report on Monday, March 2nd. Barclays boosted their target price on Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Stifel Nicolaus restated a “buy” rating and set a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. Finally, Wolfe Research upgraded Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 target price on the stock in a report on Monday, March 23rd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $49.78.

Celldex Therapeutics Stock Performance

CLDX opened at $31.34 on Monday. Celldex Therapeutics, Inc. has a one year low of $18.55 and a one year high of $35.79. The stock has a market capitalization of $2.46 billion, a PE ratio of -7.36 and a beta of 0.98. The business’s 50 day moving average price is $31.98 and its 200 day moving average price is $28.10.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.80 million. As a group, equities research analysts forecast that Celldex Therapeutics, Inc. will post -4.45 earnings per share for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.